The combined offering bundles the DiscoveRx’s cellular assays, such as PathHunter ß Arrestin and cAMP Hunter with LabChip systems to help pharmaceutical and biotechnology researchers more efficiently discover G protein-coupled receptor (GPCR) drugs.
Kevin Hrusovsky, CEO of Caliper Life Sciences, said: “This collaboration will expand the capability of Caliper’s LabChip technology into the dynamic GPCR drug discovery market, an opportunity with substantial potential due to the importance of GPCR drugs and the number of active R&D programs in neuroscience, cardiovascular, inflammation and other disease areas.”